Arm cuff trick shields kidneys during cancer surgery?
NCT ID NCT07497958
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests if temporarily restricting blood flow to an arm (called ischemic preconditioning) before kidney cancer surgery can reduce kidney damage. About 174 adults having partial nephrectomy will be randomly assigned to receive this technique or standard care. The goal is to see if this simple, non-drug method helps preserve kidney function after surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 174 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Apr 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients who are scheduled to undergo partial nephrectomy, with no specific surgical procedure limitation, including laparoscopic surgery, robot-assisted surgery, and open surgery * Aged 18 to 80 * Possess good organ function status: sufficient organ function (based on the normal values of the clinical trial center) 1. Blood routine test: WBC≥3.5×10\^9/L, absolute neutrophil count ≥1.5×10\^9/L, PLT≥75.0×10\^9/L, HGB≥80g/L; 2. Liver function: Total bilirubin ≤1.5×upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN; Exclusion Criteria: * The anesthesiologist assesses that the patient cannot tolerate general anesthesia surgery * Individuals with severe cardiovascular and cerebrovascular diseases, uncontrolled hypertension, and diabetes * Estimated glomerular filtration rate (eGFR) \< 30 ml/min/1.73m² * Horseshoe kidney * Solitary kidney * Pregnant women
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Renal cell carcinoma (RCC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
651 Dongfeng Road East, Yuexiu District, Guangzhou, P.R. China Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radioactive tracer aims to spot kidney cancer with sharper eyes
- Spleen surgery and kidney health: a hidden connection in cirrhosis?
- Can fasting two days a week slow kidney cancer? a new trial tests the idea
- Cell therapy combo aims to boost kidney cancer treatment
- First-in-Class cancer drug targets Hard-to-Treat tumors
- Immunotherapy after kidney cancer surgery: can a blood test predict who stays Cancer-Free?